Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Biovica International AB (publ)
  6. News
  7. Summary
    BIOVIC B   SE0008613731

BIOVICA INTERNATIONAL AB (PUBL)

(BIOVIC B)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Biovica Announces DiviTum«TKa results from SWOG study published in Clinical Cancer Research

09/15/2021 | 02:00am EST

Biovica announced that DiviTum®TKa results from an analysis of samples from the large SWOG S0226 study have been published in the highly ranked peer-reviewed scientific journal Clinical Cancer Research, published by the American Association for Cancer Research (AACR). The strong results support using DiviTum®TKa as a tool to monitor disease progression with endocrine therapy in women with hormone receptor positive metastatic breast cancer. As previously announced, results demonstrate that patients with low TKa levels (using a predefined cut-off) before treatment initiation will do significantly better than patients expressing high levels of TKa. Progression free survival (PFS) was 17.3 vs 11.2 months and overall survival (OS) was 58 vs 30 months, respectively. In addition, similar results were observed during treatment, where patients with low TKa showed significantly longer PFS and OS. Furthermore, results support the potential clinical use of DiviTum®TKa to identify low-TKa patients as best suited for endocrine monotherapy, whereas those with elevated TKa values appear to benefit from combination therapies. The analysis measured thymidine kinase activity (TKa) levels in 1,726 serum samples from more than 400 patients in SWOG S0226 and is the largest study to evaluate DiviTum®TKa for prognostic and serial monitoring of metastatic breast cancer. The study constitutes the foundation for the clinical validation of DiviTum®TKa in Biovica’s 510(k)-application to the FDA. DiviTum®TKa is 510(k) pending. Not available for sale in the United States.


ę S&P Capital IQ 2021
All news about BIOVICA INTERNATIONAL AB (PUBL)
11/24Biovica announces the start of the TK IMPACT trial at Washington University of St Louis
AQ
11/24Biovica announces the start of the TK IMPACT trial at Washington University of St Louis
CI
11/19Biovica International
AQ
11/19Biovica's DiviTum«TKa in three studies at SABCS 2021
AQ
11/19Biovica International AB Announces Results from Three Different Studies Using Divitum?T..
CI
11/16Biovica International
AQ
11/16Biovica's DiviTum«TKa results published in Journal of Medical Economics
AQ
10/12BIOVICA INTERNATIONA : Biovica International
AQ
10/12BIOVICA INTERNATIONAL : Announcement from Biovica International's extra general meeting
AQ
09/23BIOVICA INTERNATIONAL : Notice of extra general meeting in Biovica International AB
AQ
More news
Financials
Sales 2022 48,6 M 5,31 M 5,31 M
Net income 2022 -32,6 M -3,56 M -3,56 M
Net cash 2022 252 M 27,5 M 27,5 M
P/E ratio 2022 -36,0x
Yield 2022 -
Capitalization 1 034 M 114 M 113 M
EV / Sales 2022 16,1x
EV / Sales 2023 5,04x
Nbr of Employees 23
Free-Float 41,9%
Chart BIOVICA INTERNATIONAL AB (PUBL)
Duration : Period :
Biovica International AB (publ) Technical Analysis Chart | BIOVIC B | SE0008613731 | MarketScreener
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 36,40 SEK
Average target price 103,00 SEK
Spread / Average Target 183%
EPS Revisions
Managers and Directors
Anders Rylander Chief Executive Officer & Director
Cecilia Driving CFO, Head-Human Resource, IR & EVP
Lars Erik Holmqvist Chairman
Mattias Bergqvist Director-Clinical Development
Otti Bengtsson Gref Director-Research & Development
Sector and Competitors